MYELODOM: Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.

Sponsor
Centre Hospitalier Universitaire de Pointe-a-Pitre (Other)
Overall Status
Recruiting
CT.gov ID
NCT04260490
Collaborator
Guadeloupe Cancer Registry (Other), Martinique Cancer Registry (Other), INSERM-IRSET U1085 (Other), University of Liege (Other), University Hospital Center of Martinique (Other), Centre Hospitalier de Basse-Terre (Other)
600
2
35.4
300
8.5

Study Details

Study Description

Brief Summary

Multiple myeloma (MM) is a malignancy of plasma cells engaging in monoclonal immunoglobulin production. A strong presumption was established between exposure to pesticides and the risk of MM. The French West Indies departments of Guadeloupe and Martinique are characterized by a wide use of pesticides related to bananas plantation, particularly chlordecone which has been classified by IARC as possibly carcinogenic and has recognized hormonal properties (endocrine disruptor). The objective of this study is to measure the association between exposure to pesticide and other environmental factors in the occurrence of MM in Guadeloupe and Martinique and to estimate the proportion of cases of MM attributable to pesticide exposure. Genetic susceptibility markers and their links to environmental factors will be subsequently studies from blood samples collection.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Multiple Myeloma (MM) is a mature B-cell lymphoma characterized by monoclonal proliferation of tumor plasma cells invading the bone marrow. It is the second malignant hemopathy among Non-Hodgkin's Lymphomas. Etiology of the disease is poorly understood. Its higher incidence in black subjects suggests the existence of genetic factors. Numerous studies have evoked the role of exposure to environmental and occupational factors in the occurrence of MM such as exposure to pesticides, solvents, in particular benzene, and other petroleum derivatives, as well as work in an agricultural environment, in hairdressing and in the metallurgical and textile industries. According to the Collective Inserm expertise "Pesticides and Health", a strong presumption (++) has been established between exposure to pesticides and the risk of occurrence of MM.

    In the French West Indies (Guadeloupe, Martinique), the incidence of MM is higher than in France. These 2 departments are characterized by a major use of pesticides in connection with the banana culture developed intensively from the 1950s. These cultures successively used organochlorine insecticides, mainly β-hexachlorocyclohexane (β-HCH), technical HCH (mixture of α, β, and γ isomers of HCH), and especially chlordecone (CLD). CLD was used from 1972 to 1993 under the trade names of Kepone® (1972-1978) and then Curlone® (1982-1993) with a CLD rate of 5%. The absence of biotic and abiotic degradation of CLD has resulted in persistent soil pollution, still present today, contamination of surface and deep waters, many plant and animal products, terrestrial and marine, and then the population. CLD is a proven carcinogen in rodents, classified as a possible carcinogen by the International Agency for Research on Cancer (IARC) and has recognized hormonal properties (endocrine disruptor). CLD has been associated with an increased risk of prostate cancer in Guadeloupe. In Martinique, a geographic correlation study has shown a high incidence of MM in individuals residing on soils polluted by CLD.

    Studies on the impact of pesticides on health come up against numerous limits, in the foreground of which is the great diversity of products (more than 900 active ingredients were approved one day in France and marketed in more than 9000 different products) and the difficulty in reconstructing retrospectively and objectively the exposures of individuals due to the multiplicity of sources of exposure (leisure, gardening, domestic use).

    Mode of action of pesticides is still insufficiently documented, but some are classified as genotoxic, immunotoxic, tumor promoters or endocrine disruptors. Data available in the literature mainly relate to case-control or cohort studies on the occupational exposure of agricultural workers in industrialized countries. Measurement of this exposure is mainly made from self-administered questionnaires.

    The investigators propose to assess feasibility of a case-control study on role of exposure to pesticides, in particular to CLD and persistent pollutants, as well as other occupational exposures in the occurrence of MM in the West Indies. This study is part of the recommendations of the Inserm-InVs Chlordecone Scientific Council and action 18 of the National Interministerial Chlordecone Plan "initiate work on the link between myelomas and exposure to chlordecone".

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    600 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Multiple Myeloma in the French West Indies. Environmental and Professional Exposure to Pesticide: A Case-control Study in Guadeloupe and Martinique
    Actual Study Start Date :
    Nov 19, 2019
    Anticipated Primary Completion Date :
    Nov 1, 2022
    Anticipated Study Completion Date :
    Nov 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Cases

    Cases will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected. Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure.

    Controls

    Controls selected after stratification on department of residence, sex and age of the cases and who give a written informed consent to participate. Controls will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses in both cases and controls. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected. Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure.

    Outcome Measures

    Primary Outcome Measures

    1. Measure of association between exposure to chlordecone and risk of multiple myeloma. [Pesticide samples will be sent to the Reference Laboratory of Animal Ecology and Ecotoxicology in Liège once or twice a year. For a given patient, the time frame (questionnaire + and blood analyses) will be 12 months after inclusion.]

      The exposure measurement will be done using several complementary methods combining: Serum dosages of chlordecone + Persistent Organic Pollutant Evaluation from questionnaires Use of job-exposure matrices (benzene and other solvents), made available by the Occupational Health Department (DST) of the Institute for Health Monitoring (InVS) Use of crop-exposure matrices : the banana crop matrix developed for the Antilles by the DST of InVS in collaboration with the Interregional Epidemiology Unit (CIRE) Antilles Guyane and will be used

    Secondary Outcome Measures

    1. proportion of MM cases attributable to pesticide exposure [36 months after first inclusion]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Cases :

    • patients above 18 years old

    • with a place of residence in Guadeloupe or Martinique

    • meeting the inclusion criteria for multiple myeloma identified from hematologist, oncologist and clinicians

    • who ave a written informed consent.

    Controls :
    • individuals selected after stratification on department of residence, sex and age of the cases

    • who gave a written informed consent to participate.

    Exclusion Criteria:
    • Refusal to participate

    • subject not affiliated to a social welfare or under guardianship

    • Pregnant or lactating woman

    • Subject participating in another research including an exclusion period still in progress at the pre-inclusion

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Center of Guadeloupe Pointe-à-Pitre Guadeloupe 97159
    2 University Hospital Center of Martinique Fort-de-France Martinique 97261

    Sponsors and Collaborators

    • Centre Hospitalier Universitaire de Pointe-a-Pitre
    • Guadeloupe Cancer Registry
    • Martinique Cancer Registry
    • INSERM-IRSET U1085
    • University of Liege
    • University Hospital Center of Martinique
    • Centre Hospitalier de Basse-Terre

    Investigators

    • Principal Investigator: Jacqueline Deloumeaux, MD, CHU de la Guadeloupe

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Centre Hospitalier Universitaire de Pointe-a-Pitre
    ClinicalTrials.gov Identifier:
    NCT04260490
    Other Study ID Numbers:
    • PAP_RI2_2018/01
    First Posted:
    Feb 7, 2020
    Last Update Posted:
    Feb 7, 2020
    Last Verified:
    Feb 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Centre Hospitalier Universitaire de Pointe-a-Pitre
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 7, 2020